GE HealthCare Technologies Inc. (Nasdaq: GEHC) — Analysis Report

Report date: 2026-09-18 | Freshest data in evidence: 2026-09-17 US session

1. Tooling & Data Status — Critical Disclaimer (read first)

Before writing this report I executed all three required calls: get_stock_data, get_verified_market_snapshot, and get_indicators (with the 12 candidate indicators requested). All three returned NO_DATA_AVAILABLE — external market data tools are disabled in this deployment. Consequently:

• Exact OHLCV, price levels, indicator readings, support/resistance levels, ranges, and % price moves are not available in provided documents. I will not fabricate or estimate any of them.
• The instruction to treat get_verified_market_snapshot as the source of truth could not be fulfilled; there is no verified price/indicator snapshot to reconcile against. Any conflict-checking between tools is therefore moot, and I flag this as an unresolved gap rather than inventing a reconciled number.
• This report is built exclusively from the four source documents supplied: the QuantOrb money-flow engine snapshot, the FY2025 10-K excerpt (filed 2026-02-04), the 2026-07-23 8-K press release, and the 13F-HR snapshot as of 2026-03-31.

Everything below is either (a) directly cited from those documents, (b) explicit arithmetic on cited figures, or (c) clearly labeled methodology/interpretation.

2. The Quantitative Signal — What the Money-Flow Engine Says

Source: QuantOrb money-flow engine, as of the 2026-09-17 US session (site bake of the 05:30 HKT orb run):

Interpretation (mine, not a document fact): A Money Flow Index of 20.73 sits right at the boundary of the conventional oversold zone (commonly ≤20). This is a classic "dip-buying candidate" fingerprint: selling pressure via volume-weighted money flow has been intense enough to press the reading to the floor of its range, and the engine flags a BUY at moderate-to-high conviction (0.7668) on its own scale. Two important caveats:

1. The document itself states this is "a quantitative screen output, not a recommendation."
2. MFI is volume-weighted but price-blind to trend context. In a genuine downtrend, MFI can park itself near 20 for weeks (oversold ≠ cheap); in an uptrend, the same reading is a high-quality pullback entry. The single most important missing input is where price sits versus its 50-day and 200-day averages — not available in provided documents. This is exactly why my indicator selection below is built around establishing that trend context first.

Note the snapshot covers the 2026-09-17 session, i.e., it is one session behind "today" (2026-09-18).

3. Fundamental Context (10-K, filed 2026-02-04)

The 10-K excerpt supports a picture of a diversified, globally entrenched medtech franchise:

• Business model breadth: revenue from medical devices, consumable products, service capabilities, and AI-enabled cloud/software solutions. The consumables + service + recurring software mix is qualitatively supportive of revenue visibility (my interpretation of the as-filed description).
• Scale & reach: ~54,000 colleagues; customers in 160+ countries; ~9,700 sales professionals and ~8,900 field service engineers — the large field-service footprint is a structural moat in imaging/diagnostics (interpretation).
• Customer base: hospitals, health systems, researchers — public, private, academic, and government institutions. Broad institutional demand base; note that public/government exposure introduces budget-cycle sensitivity (interpretation).
• Operating culture: the "Heartbeat" lean business system is cited as supporting operations.

The MD&A excerpt confirms the filing covers FY2025 vs FY2024 and contains standard forward-looking-statement caveats. Segment-level financials, margins, and guidance numbers from the 10-K are not available in provided documents (only the opening excerpts were supplied).

4. Corporate Event Risk — CFO Transition (8-K, 2026-07-23)

This is the most decision-relevant corporate development on file:

• Jay Saccaro stepped down as CFO for "an expanded role outside of the medical technology industry" — per the release, not a departure amid disagreement. He remained through August 14, 2026 to ensure transition.
• George Newcomb (Controller & CAO, 38+ years of finance leadership) appointed interim CFO; a permanent successor search was commenced. As of 2026-09-18, no document indicates a permanent CFO has been named — not available in provided documents. That open seat is a live governance/communication risk: guidance updates, buyback commentary, and capital-allocation signals historically flow through the CFO.
• Critically, the same release reported preliminary Q2 2026 results and reaffirmed full-year 2026 guidance: YoY revenue growth of 5.7%, organic revenue growth of 3.5%, and adjusted EPS "ahead of prior expectation." Reaffirming guidance simultaneously with a CFO exit suggests no financial-disclosure red flag was being signaled at that time (interpretation).
• Caveats: results were preliminary and the 8-K is explicitly not an earnings call transcript. Final Q2 details, segment breakdowns, and management color are not available in provided documents. Whether FY2026 guidance still stands as of mid-September is likewise not available in provided documents (the reaffirmation is dated 2026-07-23).

Net read: fundamentals per the filings are on track; the risk is administrative/execution-framing, not (per available evidence) operational.

5. Institutional Positioning (13F-HR, as of 2026-03-31)

The quantorb filers dataset tracks 5 filer rows (explicitly not an exhaustive 13F list; quarter-end snapshot subject to up-to-45-day statutory lag — meaning this data is now ~5.5 months stale):

Derived arithmetic (from the disclosed counts): net addition of ≈ 8,190,540 shares across the five tracked filers; tracked holdings rose from ≈ 20,200,486 to ≈ 28,391,026 shares, a ~40.5% QoQ increase among tracked holders. The skew is clearly toward accumulation: two of the three largest tracked holders materially increased, one markets-affiliated entity nearly tripled, one was flat, and only one trimmed modestly.

Nuances I must flag: - The dataset does not classify filer intent. Mizuho Markets Cayman is a markets/trading entity — its position may reflect inventory or hedging rather than directional conviction (interpretation). - Only 5 filer rows are on file; total institutional sentiment cannot be inferred from this subset. - This snapshot predates the CFO announcement (July 23) — it tells us nothing about post-event institutional behavior. Post-Q1 institutional flows are not available in provided documents.

6. Indicator Selection (8 of 12) — Rationale for This Setup

Given (a) a volume-flow BUY signal at the edge of oversold and (b) an inability to verify trend context, the strategy question is: "Is this a buyable oversold condition within an intact trend, or the early leg of a downtrend?" My selection is purpose-built to answer that, with no redundancy:

1. close_200_sma — The primary trend filter. This is the single most important indicator here: it decides whether MFI ~20.73 is a pullback opportunity or a falling knife. Golden/death-cross context frames the entire trade thesis.
2. close_50_sma — Medium-term trend direction and dynamic support/resistance. If price is above a rising 50 SMA, dips toward it are the highest-probability entry zone for the money-flow signal.
3. close_10_ema — Short-term trigger. Once the oversold condition appears, the 10 EMA provides the responsive confirmation that momentum is actually turning (price reclaiming it) without waiting on slower averages. Prone to noise, hence paired with the trend filters above.
4. macd — Momentum/trend-change via crossovers and divergence. Cross-validates the volume-based MFI signal with a price-based momentum read; divergence between falling price and MACD would strengthen the bounce thesis.
5. macds — The trigger line. A crossover system requires both legs; MACD alone can't generate disciplined entry rules.
6. rsi — Price-based momentum to arbitrate against MFI 20.73. If RSI is also near/below 30, the oversold read is broad-based; if RSI is mid-range while MFI is depressed, the weakness is volume-specific (e.g., distribution into strength) — a materially different signal. Watch for divergence at the 70/30 bands.
7. boll_lb — The price-structure oversold boundary. A close back inside the lower band after tagging it is a classic mean-reversion trigger that complements the momentum indicators without duplicating them.
8. atr — Volatility measurement for stop placement and position sizing. Non-negotiable here given the open CFO transition (headline/gap risk) — ATR-normalized stops prevent both premature exits and oversized exposure.

Deliberately excluded: boll and boll_ub (this is an oversold-entry setup; the upper band adds no incremental information), macdh (redundant with the macd/macds pair for this purpose), and vwma (MFI is already volume-weighted, so VWMA's incremental value over the engine's own money-flow read is limited).

7. Conditional Trading Framework (Actionable, Staged)

Because no price data is verifiable, I express the plan as condition → action rules to be executed once live data is restored:

Scenario A — Trend intact (price above a rising 200 SMA; 50 SMA supportive): - Treat MFI 20.73 / BUY 0.7668 as a high-quality pullback entry signal. - Entry trigger: price reclaims the 10 EMA with a MACD/Signal bullish cross or RSI turning up from below ~40–45. - Entry zone: approach of the 50 SMA; optional add on a boll_lb tag-and-reclaim. - Risk: initial stop 1.5–2.0× ATR below entry (methodology — actual ATR value not available in provided documents); size so that the stop distance equals a fixed fraction of capital at risk.

Scenario B — Downtrend (price below a declining 200 SMA): - Oversold MFI readings persist in downtrends; do not buy the first signal. - Require confluence: RSI bullish divergence + MACD/Signal bullish cross + a decisive close back above/inside the boll_lb, ideally on volume confirmation. Without that, the correct action is to wait or stand aside. - Use ATR-scaled sizing; in downtrends, halve standard risk per trade (methodology).

Event-risk overlay (both scenarios): - A permanent-CFO announcement is a binary catalyst — either a de-risking event (well-regarded hire) or a re-rating event. Position sizes should assume a gap is possible; avoid maximum leverage until the seat is filled. - Watch for any guidance-revision 8-K; the last documented guidance status is the 2026-07-23 reaffirmation. - Earnings date for Q3 2026: not available in provided documents.

Unverifiable items I explicitly decline to assert: current price, any historical support/resistance bounce, 52-week range, valuation multiples, exact Q2 final results, and whether the QuantOrb signal has historically been reliable for GEHC (no backtest data exists in the documents).

8. Bottom Line

The evidence stack is constructive but incomplete. A volume-flow BUY at MFI 20.73 (strength 0.7668) marks GEHC as an oversold-bounce candidate; filings show reaffirmed FY2026 guidance, 5.7% revenue growth and 3.5% organic growth (preliminary Q2), and a strongly accumulation-skewed (though stale and narrow) 13F snapshot. The offset is an unresolved CFO seat and — most importantly for a trader — zero verifiable price context in this deployment. The trade should be treated as conditional: let the 200 SMA define the regime, the MACD/RSI/Bollinger stack confirm the turn, and ATR govern the risk. No position thesis here should be executed on the money-flow signal alone.

Key Points Summary

Overall Sentiment: Mildly Bullish (Score: 6.2/10) Confidence: Low

GEHC Sentiment Report — window 2026-09-11 to 2026-09-18 (analysis date 2026-09-18)

1. Source-by-source breakdown

Yahoo Finance news (institutional framing): Not available in provided documents. No headlines for the analysis window exist in the source set, so no news-flow signal can be read. The closest institutional evidence available is the 2026-07-23 8-K (Item 2.02 press release), which is older than the 7-day window but remains the most recent corporate disclosure on file.

StockTwits (retail sentiment): Not available in provided documents. External social data is disabled in this deployment; no bullish/bearish message ratio can be computed, and no message-count base rate exists.

Reddit (community discussion): Not available in provided documents. The r/wallstreetbets, r/stocks and r/investing feeds returned placeholders; the subreddits are silent in this dataset.

QuantOrb money-flow engine (as of 2026-09-17 US session): MFI reading of 20.73 with a BUY signal at strength 0.7668. An MFI near 20 typically indicates oversold conditions on a money-flow basis — i.e., selling pressure has been heavy but the quantitative screen flags a potential reversion/buy setup. The engine itself labels this a screen output, not a recommendation. This is the only time-stamped data point inside the analysis window.

13F-HR institutional holdings (as of 2026-03-31, statutory lag up to 45 days): Of 5 tracked filers, three added materially to positions — Barrow Hanley (+82.7%, now 11,884,588 shares), Mizuho Markets Cayman (+173.2%, 3,068,500 shares), Hotchkis & Wiley (+10.4%, 9,967,873 shares) — while River Road trimmed modestly (-4.8%) and Locust Wood was flat (-617 shares). Net institutional posture in this snapshot is accumulation. Note: this snapshot predates the analysis window by roughly six months and is not exhaustive of all 13F filers.

10-K (filed 2026-02-04): Descriptive only — global medtech/pharmaceutical diagnostics/AI-cloud franchise, ~54,000 colleagues, customers in 160+ countries, ~9,700 sales professionals and 8,900 field service engineers. No sentiment content.

8-K (2026-07-23): CFO Jay Saccaro stepping down (departing 2026-08-14); Controller/CAO George Newcomb appointed interim CFO; permanent-successor search underway. Alongside the leadership change, preliminary Q2 2026 results showed revenue growth of 5.7% YoY, organic revenue growth of 3.5%, adjusted EPS ahead of prior expectation, and full-year 2026 guidance reaffirmed. Management framed the results as "reflecting business momentum."

2. Cross-source divergences and alignments

• The classic retail-vs-news divergence check cannot be performed: both social sources returned "unavailable" placeholders, so all cross-source comparison is restricted to the quantitative money-flow signal versus the statutory/regulatory record.
• Alignment: the QuantOrb BUY signal (0.7668 strength) is directionally consistent with the March-2026 13F accumulation pattern (three of five tracked filers adding, two large adds of 82.7% and 173.2%). Both lean constructive on GEHC.
• Tension: an MFI of 20.73 indicates the stock has been on the receiving end of persistent money outflow/oversold pressure in the current session context, whereas the fundamentals (reaffirmed guidance, EPS ahead of expectations) and historical institutional accumulation point the other way. This is an oversold-vs-fundamental tension rather than a directional conflict.
• Governance overhang: the CFO transition (announced 2026-07-23, permanent successor still unfilled as of the last available disclosure) is the main unresolved risk item and sits against otherwise positive results framing.

3. Dominant narrative themes

1. Business momentum vs. CFO churn — reaffirmed guidance and EPS beat framing, offset by an unresolved permanent-CFO search.
2. Institutional accumulation — deep-value/quant-style filers (Barrow Hanley, Hotchkis & Wiley, Mizuho) building positions as of 2026-03-31.
3. Oversold money-flow setup — MFI ~20.73 with a BUY screen signal into the 2026-09-17 session.
4. Durable franchise — diversified medtech/diagnostics/AI-software model, 160+ country footprint, recurring service/consumables mix (per 10-K).

4. Catalysts and risks surfaced by the data

• Catalysts: potential money-flow mean reversion from oversold levels (MFI 20.73 + BUY signal); possible completion of the permanent CFO appointment (timing not available in provided documents); continued confirmation of FY2026 guidance trajectory.
• Risks: executive-continuity uncertainty while the CFO seat is held on an interim basis; the possibility that the oversold money-flow reading reflects a genuine deterioration in institutional flows rather than a temporary dip; absence of any news or social sentiment data for the actual analysis window means any narrative shift in the past seven days cannot be detected; 13F data is a stale (2026-03-31) snapshot, not real-time positioning.

5. Summary table

Confidence and caveats

Confidence is low: the two fastest-moving sentiment sources (StockTwits, Reddit) and the institutional news feed all returned unavailable placeholders, so no live sentiment signal for 2026-09-11 to 2026-09-18 exists. The read rests on one quantitative data point (MFI/BUY), a stale 13F snapshot from 2026-03-31, and filings predating the window. The Mildly Bullish band reflects the confluence of an oversold BUY screen signal, historical institutional accumulation, and reaffirmed-guidance fundamentals, discounted heavily for data sparsity and the open CFO-transition risk. This is sentiment signal for the trader to weigh alongside fundamentals and technicals — not a price call, and the QuantOrb output is explicitly a screen result, not a recommendation.

GEHC — News & Trend Research Report (Analysis Date: 2026-09-18)

0. Data Availability Notice (read first)

All eight external data pulls executed for this workflow returned NO_DATA_AVAILABLE — the external market-data tools (company news, global news, FRED macro indicators, prediction markets) are disabled in this deployment. Accordingly, every claim below is sourced exclusively from the four permitted source documents: [FACTS] QuantOrb money-flow snapshot, [FILING] SEC 10-K excerpt, [EIGHTK] SEC 8-K press release, and [THIRTEENF] 13F-HR snapshot. Anything outside their coverage is explicitly flagged as not available in provided documents. No prices, macro prints, market-implied probabilities, or news events have been fabricated.

1. Company Snapshot: GE HealthCare Technologies Inc (GEHC, Nasdaq)

• Sector / Industry: Health Care / Health Care Equipment (per [FACTS])
• Business profile (per 10-K filed 2026-02-04): Global provider of advanced medical technology, pharmaceutical diagnostics, and AI/cloud/software solutions; ~54,000 employees; customers in 160+ countries; ~9,700 sales professionals and ~8,900 field service engineers; revenue from devices, consumables, service, and AI-enabled software; customers are hospitals, health systems, researchers, and public/academic/government institutions.
• Relevance for traders: A large-cap, globally diversified medtech franchise with a meaningful recurring/service and consumables component. The 10-K excerpt does not provide segment financials, margins, geographic revenue splits, or guidance figures — not available in provided documents.

2. Quantitative Signal — Most Recent Dated Data Point

• Money-flow snapshot (2026-09-17 US session, [FACTS]): MFI reading 20.73, signal BUY, signal strength 0.7668. This is the freshest data point in the entire document set — one trading day before the analysis date.
• Interpretation (clearly flagged as analyst interpretation, not document content): An MFI in the low 20s is conventionally read as a low/oversold-adjacent money-flow reading; paired with a BUY screen output of above-average strength (0.7668), the engine is flagging accumulation conditions after depressed money flow.
• Critical caveat (from the document itself): "The signal is a quantitative screen output, not a recommendation." It carries no fundamental, valuation, or news context and should not be traded standalone.

3. Fundamentals & Corporate Events (8-K, 2026-07-23)

The 8-K is an Item 2.02 press release — not an earnings call transcript — and carries two distinct pieces of information:

a) Preliminary Q2 2026 results ("business momentum"): - Revenue growth +5.7% YoY; organic revenue growth +3.5% - Adjusted EPS performance ahead of prior expectation - Full-year 2026 guidance reaffirmed

b) CFO transition (the more significant event): - Jay Saccaro stepped down as VP & CFO for a role outside the medtech industry; remained through August 14, 2026 - George Newcomb (Controller & Chief Accounting Officer, 38+ years of finance leadership) appointed interim CFO - Search for a permanent successor commenced as of the 8-K date - CEO Peter Arduini credited Saccaro with "driving financial discipline and strategic investments aligned to our capital allocation strategy"

Trading relevance: As of the analysis date (2026-09-18), GEHC has operated under an interim CFO for over a month, and the outcome of the permanent CFO search is not available in provided documents. CFO transitions at reaffirmed-guidance medtechs are typically manageable, but they are a classic event-risk/catalyst window (permanent appointment announcement, any guidance nuance in the next formal report).

4. Institutional Positioning (13F-HR, positions as of 2026-03-31)

The tracked quantorb filer snapshot (5 rows, not exhaustive; subject to the statutory ~45-day lag and now ~5.5 months stale) shows net accumulation among the tracked holders:

• Net arithmetic across the five tracked filers: +8,190,540 shares added vs. −68,278 trimmed (adds of ~8.26M, trims of ~0.07M) — a heavily one-sided accumulation skew in this dataset.
• Two value-oriented managers (Barrow Hanley, Hotchkis & Wiley) account for the bulk of the adds; Mizuho's Cayman markets affiliate naming suggests a possible trading/derivatives-desk position rather than a long-only allocation (interpretation, not stated in the document).
• Caveats: stale as of 2026-03-31; the status of a more recent (2026-06-30) snapshot is not available in provided documents; the tracked list is not the full 13F universe, so this cannot be read as overall institutional sentiment.

5. Macro & Global Backdrop

• Macro indicators (CPI, core PCE, unemployment, fed funds, 10-year Treasury, yield curve): all pulls returned NO_DATA_AVAILABLE — not available in provided documents. No directional macro read (rates, inflation, labor) can be responsibly attached to GEHC in this report.
• Global/geopolitical news: not available in provided documents. Note the structural exposure, however: the 10-K describes customers in 160+ countries, meaning hospital capex cycles, tariffs/trade policy, FX translation, and China/international diagnostics demand are first-order swing factors — but any assessment of their current state is not possible from the permitted sources.
• Prediction markets (Fed rate cut, recession 2026, sector events): not available in provided documents. No market-implied probabilities can be cited.

6. Actionable Insights & Watch Items

1. Signal-fundamental alignment (constructive): The freshest data point (2026-09-17) shows a BUY money-flow screen at strength 0.7668 with MFI at 20.73, and the most recent fundamental disclosures show growth (Q2: +5.7% reported / +3.5% organic), an EPS beat vs. prior expectation, and reaffirmed FY2026 guidance. Documents support a stable-fundamentals + early-accumulation-signal setup — as a screen, not a recommendation.
2. Primary catalyst to monitor — permanent CFO appointment: Unresolved since the 2026-07-23 8-K. An announcement (or a Q3 earnings date approaching with the seat still interim) is the clearest identifiable near-term event risk/trigger in the documents.
3. Confirmation gap — recent news: Whether anything material happened to GEHC between 2026-09-11 and 2026-09-18 is not available in provided documents. Any trade premised on "no adverse news" is unverified here; verify the tape before execution.
4. 13F skew supports the accumulation thesis, but verify freshness: The +8.2M net share add among tracked filers (Q1 2026) is directionally supportive; treat as background evidence only given the 5.5-month staleness.
5. Macro blind spot: With rates, inflation, and hospital-capex-relevant macro data unavailable, position sizing should assume normal macro volatility is unpriced in this analysis.
6. Standard caveats: MFI 20.73/BUY is a point-in-time screen on one session's money flow; it says nothing about valuation (current price, P/E, EPS levels — not available in provided documents), the competitive landscape, or Q3 results timing.

Key Points Summary Table

Prepared for the trading desk workflow on GEHC, 2026-09-18. All quantitative figures above are quoted verbatim from the permitted source documents; interpretive commentary is flagged as such.

All four external data tools (get_fundamentals, get_balance_sheet, get_cashflow, get_income_statement) returned NO_DATA_AVAILABLE — external market data access is disabled in this deployment. The report below is therefore built exclusively from the four permitted source documents: the QuantOrb money-flow snapshot [FACTS], the 10-K excerpt [FILING], the July 2026 8-K press release [EIGHTK], and the 13F-HR holdings snapshot [THIRTEENF]. Items outside these documents are flagged as "not available in provided documents."

GE HealthCare Technologies Inc. (GEHC) — Fundamental Research Report

Analysis date: 2026-09-18 | Ticker: GEHC | Sector: Health Care | Industry: Health Care Equipment (sector/industry per [FACTS]; Nasdaq listing per [EIGHTK])

1. Executive Summary

GEHC enters the 2026-09-18 analysis window with a constructive fundamental narrative and a supportive — though partial — evidence base:

• Business momentum: The company's July 23, 2026 8-K reported preliminary Q2 2026 results with revenue growth of 5.7% YoY and organic revenue growth of 3.5%, with adjusted EPS ahead of prior expectation and full-year 2026 guidance reaffirmed [EIGHTK].
• Quantitative signal: The QuantOrb money-flow engine logged an MFI reading of 20.73 with a BUY signal (signal strength 0.7668) as of the 2026-09-17 US session — a low money-flow reading paired with a strong-strength buy output [FACTS]. This is explicitly a screen output, not a recommendation.
• Institutional accumulation: The most recent 13F snapshot (positions as of 2026-03-31) shows heavy net adding by value-oriented managers, led by Barrow Hanley (+82.7%) and Mizuho Markets Cayman (+173.2%) [THIRTEENF].
• Key open risk: A CFO transition — Jay Saccaro stepped down (departed August 14, 2026), with Controller/CAO George Newcomb serving as interim CFO and a permanent-successor search underway [EIGHTK].

Material gaps remain: absolute financial statement data (income statement, balance sheet, cash flow) is not available in provided documents — neither from the disabled tools nor from the 10-K excerpt, which contains only narrative openings and no numeric tables.

2. Company Profile (from SEC 10-K, filed 2026-02-04) [FILING]

The 10-K excerpt (Item 1, Business) describes GE HealthCare as follows:

• Positioning: "A leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world's most complex diseases."
• Heritage: Serving patients and providers for nearly 130 years.
• Workforce: Approximately 54,000 colleagues, with a lean operational culture supported by its "Heartbeat" business system.
• Revenue model: Generates revenue from the sale of (1) medical devices, (2) consumable products, (3) service capabilities, and (4) AI-enabled cloud and software solutions — a mix of capital equipment, recurring consumables/service, and software.
• Geographic reach: Customers in over 160 countries.
• Commercial infrastructure: A global team of approximately 9,700 sales professionals and 8,900 field service engineers — a large installed-base service footprint typical of a sticky, recurring-revenue medtech franchise.
• Customer base: Hospitals, health systems, and researchers, including public, private, academic, and government institutions — a diversified payer/customer mix, but one exposed to hospital capital-spending cycles and government/public-institution budget dynamics.

Financial history detail: The 10-K's Item 7 MD&A covers fiscal years ended December 31, 2025 and 2024 (with FY2023 comparisons referenced to the prior-year 10-K). However, the excerpt contains only the opening narrative — no revenue, margin, earnings, debt, or cash-flow figures are included, so FY2025/FY2024 quantitative results are not available in provided documents.

3. Recent Fundamental Developments — Q2 2026 Preliminary Results & CFO Transition (8-K, filed 2026-07-23) [EIGHTK]

This is the most substantive recent fundamental disclosure available, and it is explicitly an Item 2.02 press release, not an earnings call transcript.

3.1 Preliminary Q2 2026 Results

Interpretation points for traders: - The gap between reported revenue growth (+5.7%) and organic growth (+3.5%) implies roughly ~2 percentage points of growth from non-organic sources (e.g., FX or M&A) — the press release excerpt does not break down the drivers, so attribution is not available in provided documents. - Adjusted EPS "ahead of prior expectation" alongside reaffirmed guidance signals operational execution in line-to-better-than-internal-plan as of late July 2026. - Because these are preliminary results furnished under Item 2.02, final audited Q2 figures (in a subsequent 10-Q) are not available in provided documents.

3.2 CFO Transition — the Central Governance Event

• Jay (James) Saccaro stepped down as VP and CFO for an expanded role outside of the medical technology industry, after roughly three years in the seat, during which — per CEO Peter Arduini — he "played a key role in driving financial discipline and strategic investments aligned to our capital allocation strategy."
• George Newcomb, currently Controller and Chief Accounting Officer with 38+ years of finance leadership experience, was appointed interim CFO. Saccaro remained through August 14, 2026 to support transition; a permanent-successor search has commenced.
• Trader takeaway: As of the 2026-09-18 analysis date, the permanent CFO seat has nominatively been vacant for over a month post-departure (no announcement of a permanent hire appears in the provided documents). This is a watch item rather than a demonstrated problem — guidance was reaffirmed and the interim is an internal accounting veteran — but CFO departures to roles outside the industry can precede periods of forecasting conservatism or capital-allocation shifts. Confirmation or refutation arrives with the next scheduled earnings report (date not available in provided documents) and the permanent-CFO announcement.

4. Institutional Ownership — 13F-HR Snapshot (positions as of 2026-03-31) [THIRTEENF]

Five tracked institutional filer rows for GEHC (dataset caveat: not exhaustive; a quarter-end snapshot subject to a statutory reporting lag of up to 45 days — meaning this data is now ~5.5 months stale as of the analysis date):

Reading the tape: - Net accumulation among the tracked top holders: 4 of 5 filers were flat-to-adders, with the two largest value-style managers (Barrow Hanley, Hotchkis & Wiley — both known deep-value shops) collectively adding over 6.3 million shares. Mizuho Markets Cayman's +173.2% is proportionally the largest but from a smaller base; as a markets/principal entity, its positioning may not reflect long-only conviction. - Timing caveat is critical: this snapshot is as of 2026-03-31, i.e., before the July 23 CFO-transition 8-K and before the September money-flow reading. It cannot be read as a reaction to either event. Updated Q2 (June 30) and Q3 (September 30) 13F data are not available in provided documents. - Aggregate institutional ownership percentage, total shares outstanding, and positions of the true top holders (e.g., index complexes) are not available in provided documents.

5. Quantitative Money-Flow Signal (as of 2026-09-17 US session) [FACTS]

• MFI reading: 20.73 — on the standard 0–100 Money Flow Index scale, a reading in the low-20s sits at/near the conventional "oversold" zone (<20–30), indicating selling pressure has dominated recent money flow.
• Signal: BUY, signal strength 0.7668 — the engine outputs a buy despite the low MFI, consistent with an oversold-reversal style screen.
• Critical framing: the source explicitly states this is "a quantitative screen output, not a recommendation." It reflects the 2026-09-17 US session (site bake of the 05:30 HKT orb run) and carries no information about GEHC's fundamentals, valuation, or forward earnings.
• Underlying price, volume, and market-cap inputs to the MFI calculation are not available in provided documents.

Synthesis: A low-MFI/BUY pairing tells traders that recent money flow has been weak (potentially oversold) while the screen flags buy-side conditionality — most useful as a timing/tactical overlay, to be weighed against the fundamental picture (solid preliminary Q2 print, reaffirmed guidance, open CFO-search uncertainty).

6. Data Gaps — Explicitly Not Available in Provided Documents

The following, which a full fundamental review would normally include, could not be sourced from the permitted documents (and the external data tools returned NO_DATA_AVAILABLE):

• Income statement: revenue dollar amounts, gross/operating/net margin, net income, EPS (absolute) — not available in provided documents
• Balance sheet: cash, debt, leverage, working capital — not available in provided documents
• Cash flow statement: operating cash flow, free cash flow, capex — not available in provided documents
• FY2025/FY2024 quantitative results (MD&A body of the 10-K excerpt omitted) — not available in provided documents
• Specific FY2026 guidance numbers (guidance reaffirmed, but no figures given) — not available in provided documents
• Share price, market cap, valuation multiples, dividend/buyback activity — not available in provided documents
• Segment or geographic revenue breakdowns — not available in provided documents
• Risk factors, litigation, tariff/supply-chain commentary — not available in provided documents
• Q3 2026 earnings date; any filings made during the past week (2026-09-11 to 2026-09-18) — not available in provided documents; the most recent SEC document supplied is the 2026-07-23 8-K

7. Actionable Insights for Traders

1. Fundamental trajectory is intact per the latest disclosure. The only hard performance data available — preliminary Q2 2026 — shows +5.7% reported / +3.5% organic revenue growth with adjusted EPS beating prior internal expectation and FY2026 guidance reaffirmed [EIGHTK]. Any bear case must reconcile with this, not just the CFO exit.
2. Treat the CFO transition as an unresolved, watchable overhang — not a red flag yet. Departure (Aug 14, 2026) + interim (George Newcomb, 38 yrs experience) + active permanent search [EIGHTK]. The risk is process/continuity (guidance philosophy, capital allocation) rather than a disclosed deterioration. Position sizing around event risk (permanent CFO announcement; next earnings report) is the actionable response; the timing of both is not available in provided documents.
3. The quant signal supports an oversold-timing lens. MFI 20.73 (weak recent money flow) + BUY at 0.7668 strength [FACTS] is consistent with an entry-timing setup, but is a screen output only and must not be treated as a recommendation. Without price/valuation data, the signal cannot be validated against fundamentals.
4. Use 13F data with a staleness discount. The strong net adding by Barrow Hanley (+82.7%) and Hotchkis & Wiley (+10.4%) is genuine regulatory evidence of value-manager accumulation, but it predates the CFO news by ~4 months and the analysis date by ~5.5 months [THIRTEENF]. It speaks to baseline institutional sponsorship, not to post-July positioning.
5. Recurring-revenue quality is a structural positive. The 10-K's description of a consumables + services + AI/software revenue model layered on a large installed base (8,900 field service engineers, 160+ countries) [FILING] implies revenue durability that softens the blow of capital-equipment cyclicality — a qualitative support for the reaffirmed guidance, though quantification is not available in provided documents.
6. Verification checklist before acting: (a) the Q2 2026 10-Q final figures; (b) the permanent CFO announcement; (c) FY2026 guidance specifics; (d) the next earnings report date — all not available in provided documents and should be confirmed from primary sources.

8. Key Points Summary Table

Bottom line: The available evidence paints GEHC as a fundamentally steady large-cap medtech (growing revenue, guidance reaffirmed, accumulating value-oriented institutions) navigating a mid-stream CFO transition, with a quantitative buy/oversold reading as of 2026-09-17. The absence of financial-statement and price data in the provided documents means traders should validate valuation, leverage, and cash-flow support before acting, and treat both the money-flow signal and the 13F snapshot as conditional, time-lagged inputs rather than trade triggers.